Core Viewpoint - Appili Therapeutics Inc. announced the termination of the arrangement agreement with Aditxt, effective May 31, 2025, which may result in a termination fee of USD 1,250,000 payable by Aditxt [1][2]. Group 1: Termination of Arrangement Agreement - Aditxt delivered a notice to terminate the arrangement agreement dated April 1, 2024, with Appili and its subsidiary Adivir, with the termination effective as of May 31, 2025 [1]. - The termination fee due to Appili is USD 1,250,000, which will be reduced by amounts previously paid by Aditxt to extend the agreement's outside date, resulting in a net payable amount of USD 1,000,000 [2]. Group 2: Company Overview - Appili Therapeutics is a biopharmaceutical company focused on developing drugs for infectious diseases and medical countermeasures, aiming to address urgent infections with unmet needs [4]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate against biological threats, and a topical antiparasitic treatment [4].

Core Viewpoint - Appili Therapeutics is advancing its biodefense vaccine candidate, ATI-1701, aimed at preventing tularemia, a serious bacterial infection, with recent research highlighting its potential role in controlling outbreaks [1][3]. Group 1: Vaccine Development - ATI-1701 is a first-in-class live-attenuated vaccine targeting Francisella tularensis, the pathogen responsible for tularemia, which is classified as a Category A pathogen due to its high infectiousness [4]. - The vaccine is being developed to protect military personnel from tularemia, with insights from recent research expected to refine immune response targets for its clinical advancement [2][3]. - There is currently no approved vaccine for tularemia in the United States or other major markets, positioning ATI-1701 as a critical medical countermeasure [3][4]. Group 2: Research Collaboration - The research published in Frontiers in Bacteriology consolidates findings on immune responses to F. tularensis, identifying key correlates of protection and pathways for effective vaccine development [2]. - Collaboration with researchers from the United States Air Force Academy and other institutions is enhancing the understanding of host immune responses, which is essential for the vaccine's development [2][3]. Group 3: Company Overview - Appili Therapeutics is focused on developing therapies for infectious diseases, with a portfolio that includes various anti-infectives and a commitment to addressing urgent medical needs [5]. - The company aims to systematically identify and develop novel therapies to combat life-threatening infections, positioning itself at the forefront of the global fight against infectious diseases [5].

Core Viewpoint - Appili Therapeutics has secured new patents for its oral formulation of metronidazole, LIKMEZ, enhancing its market protection and supporting its commercialization efforts [1][2][3] Patent Protection - The newly granted patents will expire in 2039 and provide comprehensive protection for LIKMEZ, covering its unique taste-masked composition and therapeutic applications [2] - The U.S. patent has been listed in the FDA's Orange Book, which is crucial for ensuring additional protection for the formulation [2][3] Product Overview - LIKMEZ is the first FDA-approved ready-made suspension of metronidazole, specifically designed for treating antimicrobial-resistant infections, particularly beneficial for patients with dysphagia [4] - The formulation aims to improve stability and palatability, which are essential for patient adherence to medication and better treatment outcomes [3] Commercialization Efforts - Saptalis Pharmaceuticals, the partner of Appili, is planning to re-launch LIKMEZ under its own label in May 2025, leveraging the newly granted patent for commercialization activities [3][4] - The collaboration with Saptalis emphasizes the commitment to bringing innovative pharmaceutical solutions to market [5][6] Company Background - Appili Therapeutics focuses on developing therapies for infectious diseases and aims to address urgent medical needs through a diverse pipeline of anti-infectives [7][9] - The company is strategically positioned to tackle life-threatening infections, with a proven management team leading its initiatives [9]

Core Viewpoint - Appili Therapeutics Inc. has submitted four new funding proposals totaling US$117.5 million to advance treatments for infectious diseases, aligning with public health priorities [1] Funding Opportunities - The company applied for two solicitations from the National Institute of Allergy and Infectious Diseases (NIAID), seeking US$46.3 million for a vaccine against invasive fungal infections and US$36.4 million for an antifungal monoclonal antibody targeting a rare fungal infection [2] - Additionally, two proposals were submitted to the US Medical CBRN Defense Consortium (MCDC) for a total of US$34.8 million, including US$20.1 million for a broad-spectrum treatment for viral infections and US$14.7 million for a direct-acting antiviral [3] Consortium Membership - Appili has been selected to join the MCDC, which has awarded over US$7 billion in project funding, enhancing the company's role in developing medical countermeasures [4] Previous Funding Success - The company has raised approximately US$33.2 million in prior government funding awards, which have supported the development of various pipeline programs, including ATI-1701 and LIKMEZ™ [6] Update on USAFA Awards - Appili received an update regarding its arrangement with the United States Air Force Academy (USAFA) for ATI-1701, with a total of approximately US$14 million awarded, of which US$11.6 million has been allocated for services [7][10] - A modification to the USAFA Cooperative Agreement has resulted in an increased General & Administrative overhead recovery rate, benefiting the company financially [8] Going-Private Transaction - The company is in the process of a going-private transaction with Aditxt Inc., which has received shareholder and court approvals, with an extended deadline for financing set to March 31, 2025 [11][12][13]